Pharmacogenomics of psychiatric disorders

Trends in Pharmacological Sciences

Volumn 22, Issue 2, 2001, Pages 75-83

  Pickar, David ^a   Rubinow, Katya ^a  

^a Univ S Carolina Sch Med Vice P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; METRIFONATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT; XANOMELINE;

AFFECTIVE NEUROSIS; ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG MECHANISM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MENTAL DISEASE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS;

EID: 0035252388     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01603-5     Document Type: Review

References (80)

1. Genetics and schizophrenia
2. Schizophrenia: Genes and environment
3. Polygenic inheritance in psychiatric disorders
4. Genetic linkage and complex diseases, with special reference to psychiatric disorders
5. Alternative phenotypes for the complex genetics of schizophrenia
6. Genetic association studies in psychiatry: Recent history
7. Psychiatric genetics '99: The challenges of psychopharmacogenetics
8. Schizophrenia: The epidemiological horizon
9. Clozapine for the treatment-resistant schizophrenic: A double-blind placebo comparison with chlorpromazine
10. Clincal and biological response to clozapine in patients with schizophrenia
11. Cloning of the gene for a human D4 receptor with high affinity for the antipsychotic clozapine
12. Multiple D4 receptor variants in the human population
13. Prospects for pharmacotherapy of schizophrenia
14. 2A receptors in antipsychotic activity
15. An overview of the mechanism of action of clozapine
16. 2 involvement in the mechanism of action of hallucinogenic agents
17. Multiple serotonin receptors: Clinical and experimental aspects
18. One month prevalence of mental disorders in the US: Based on five epidemiological catchment area (ECA) sites
19. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene
20. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
21. Modified structure of the human serotonin transporter promoter
22. Placebo effect in randomized, controlled studies of acute bipolar mania and depression
23. Placebo as a treatment for depression
24. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?
25. Molecular genetics of Alzheimer's disease
26. Genetics and the etiology of schizophrenia and bipolar disorder
27. A molecular and cellular theory of depression
28. Corticotropin-releasing factor, norepinephrine and stress
29. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine
30. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients
31. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
32. Dopamine D4 receptor 48-bp repeat polymorphism: No association with response to antipsychotic treatment, but association with catatonic schizophrenia
33. Efficacy and side effects of clozapine: Testing for association with allelic variation in the dopamine D4 receptor gene
34. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects
35. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia
36. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response
37. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistini patients
38. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response
39. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population
40. 2A gene and schizophrenia: Relation to phenotype and drug response variability
41. 2A receptors and clozapine response
42. 2A receptor gene and response to clozapine
43. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
44. 2A receptor and clinical response to clozapine
45. 2A receptor gene
46. 2A receptor gene and the antipsychotic response to clozapine
47. 2 receptor gene locus: Association with schizophrenia or treatment response not detected
48. 2A receptor and response to clozapine
49. 2C Cys23Ser polymorphism
50. 2C receptor gene
51. 2C receptor
52. 5A gene in depression, psychosis and antipsychotic response
53. Serotonin-6 receptor variant (C267T) and clinical response to clozapine
54. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
55. The serotonin transporter and clozapine response
56. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response
57. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients
58. Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in Jewish Israeli schizophrenic patients
59. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia
60. Association between HLA-A1 allele and schizophrenia gene(s) in patients refractory to conventional neuroleptics but responsive to clozapine medication
61. Cytochrome P4502D6 genotype does not determine response to clozapine
62. Apolipoprotein Eε4 and clinical phenotype in schizophrenia
63. No evidence for association of α1a adrenoceptor gene polymorphism and clozapine-induced urinary incontinence
64. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response
65. Serotonin transporter gene polymorphism and antidepressant response
66. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
67. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene
68. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
69. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders
70. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders
71. Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment
72. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease
73. Apolipoprotein E genotype and gender influence response to tacrine therapy
74. Treatment outcome of tacrine therapy depends on apolipoprotein E genotype and gender of the subject with Alzheimer's disease
75. ApoE genotype and clinical outcome in Alzheimer's disease
76. ApoE genotyping and response to drug treatment in Alzheimer's disease
77. The apolipoprotein ε4 allele and the response to tacrine therapy in Alzheimer's disease
78. The ability of THA treatment to increase cortical α waves is related to apolipoprotein E genotype of Alzheimer's disease patients
79. A 30 week randomized controlled clinical trial of high doses of tacrine in patients with Alzheimer's disease
80. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease